NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,265,544 | -19.5% | 378,020 | +6.4% | 0.04% | -16.3% |
| Q2 2023 | $9,030,785 | +6.2% | 355,263 | +51.0% | 0.04% | +2.4% |
| Q1 2023 | $8,506,493 | +0.9% | 235,311 | +10.5% | 0.04% | -10.6% |
| Q4 2022 | $8,429,929 | +0.5% | 212,877 | +18.2% | 0.05% | +4.4% |
| Q3 2022 | $8,389,000 | -36.4% | 180,032 | -40.2% | 0.04% | -33.8% |
| Q2 2022 | $13,198,000 | -19.1% | 301,125 | +33.5% | 0.07% | -26.1% |
| Q1 2022 | $16,314,000 | +6.7% | 225,545 | +19.6% | 0.09% | +9.5% |
| Q4 2021 | $15,290,000 | +673.4% | 188,598 | +1230.7% | 0.08% | +500.0% |
| Q1 2021 | $1,977,000 | +25.9% | 14,173 | +56.3% | 0.01% | +7.7% |
| Q4 2020 | $1,570,000 | -25.6% | 9,068 | -63.0% | 0.01% | -64.9% |
| Q3 2019 | $2,109,000 | +88.3% | 24,532 | +59.2% | 0.04% | +54.2% |
| Q4 2016 | $1,120,000 | -89.9% | 15,414 | -85.5% | 0.02% | -90.0% |
| Q3 2016 | $11,096,000 | +112.4% | 106,298 | +50.1% | 0.24% | +61.7% |
| Q2 2016 | $5,223,000 | – | 70,816 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
| Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
| Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
| Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
| Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
| Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
| Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
| ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
| PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |